Stan Bernard outlines the seven ways for pharmas to ensure successful execution of action steps following brand ‘war games’.
The seven ways for pharmas to ensure successful execution of action steps following brand "war games."
Biopharma companies are increasingly leveraging product portfolios to own and dominate strategically important therapeutic areas.
Answer 12 key questions to determine if your brand team is leveraging today’s winning competitive strategies and actions.
For years, many companies have competed to demonstrate that their products could achieve the holy grail in type 2 diabetes (T2D): cardiovascular (CV) risk reduction. According to the American Diabetes Association, pharma companies to date have spent over $2 billion and tested 138,000 patients in company-sponsored CV-risk reduction T2D trials, including the recent large-scale TECOS, SAVOR, EXAMINE, and ELIXA studies.
What can companies do for an encore when their own blockbuster product is threatened by branded or generic competitors?